Adagene Inc. (NASDAQ:ADAG) Shares Purchased by Mill Creek Capital Advisors LLC

Mill Creek Capital Advisors LLC boosted its stake in shares of Adagene Inc. (NASDAQ:ADAG) by 119.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 199,610 shares of the company’s stock after purchasing an additional 108,702 shares during the quarter. Mill Creek Capital Advisors LLC’s holdings in Adagene were worth $397,000 as of its most recent SEC filing.

Separately, Catalina Capital Group LLC raised its holdings in Adagene by 129.2% in the fourth quarter. Catalina Capital Group LLC now owns 29,198 shares of the company’s stock valued at $58,000 after acquiring an additional 16,461 shares in the last quarter. 9.51% of the stock is owned by hedge funds and other institutional investors.

Adagene Stock Down 1.2 %

NASDAQ:ADAG opened at $1.70 on Tuesday. Adagene Inc. has a 1 year low of $1.68 and a 1 year high of $3.78. The stock has a 50-day simple moving average of $1.96 and a 200-day simple moving average of $2.35.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. HC Wainwright boosted their price target on shares of Adagene from $5.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, January 27th. Morgan Stanley cut shares of Adagene from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 31st.

Adagene Company Profile

Adagene Inc, a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors.